Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend ...

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Sanofi SA (SNY) stock saw a modest uptick, ending the day at $49.19 which represents a slight increase of $1.04 or 2.16% from the prior close of $48.15. The stock opened at $48.57 and touched a low of ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sanofi (SNYNF – Research Report) and Cencora ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, undisclosed central nervous system target.

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

“Both companies are ‘houses of brands’, in other words a collection of well-diversified luxury businesses serving multiple ...

Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (SNYNF – Research Report) today and set a price target of €115.00. The ...

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

MRT-5410 is under clinical development by Sanofi and currently in Phase II for Unspecified Influenza Virus Infections.

SP-0230 is under clinical development by Sanofi and currently in Phase II for Neisseria meningitidis Infections.